| EFX |
Report |
2Q26 adjusted EPS |
BEAT |
pred ~$2.24 vs. cons $2.21 |
MEDIUM |
| EFX |
Report |
2Q26 reported revenue |
IN-LINE |
pred ~$1.715B vs. cons $1.700B |
MEDIUM |
| EFX |
Report |
2Q26 organic local-currency revenue growth |
BEAT |
pred ~9.6% vs. cons 9.3% |
LOW |
| EFX |
Guide |
3Q26 reported revenue guidance midpoint |
LOWER |
guide ~$1.705B vs. cons $1.710B (3Q26) |
MEDIUM |
| EFX |
Guide |
3Q26 adjusted EPS guidance midpoint |
LOWER |
guide ~$2.27 vs. cons $2.28 (3Q26) |
MEDIUM |
| EFX |
Guide |
FY26 reported revenue guidance midpoint |
LOWER |
guide ~$6.745B vs. cons $6.754B (FY26) |
MEDIUM |
| EFX |
Guide |
FY26 adjusted EPS guidance midpoint |
LOWER |
guide ~$8.54 vs. cons $8.56 (FY26) |
MEDIUM |
| EFX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| EFX |
Return |
5-day cumulative residual |
-4.5% (FOLLOW-THROUGH) |
A modest 2Q EPS beat of ~$2.24 versus $2.21 consensus is likely outweighed by an unchanged FY26 EPS midpoint of ~$8.54 versus $8.56 consensus, implying softer second-half math and downward out-period revisions. |
MEDIUM |